z-logo
open-access-imgOpen Access
Driving Neuronal Differentiation through Reversal of an ERK1/2-miR-124-SOX9 Axis Abrogates Glioblastoma Aggressiveness
Author(s) -
Hanna Sabelström,
Rebecca Petri,
Ksenya Shchors,
Rahul Jandial,
Christin Schmidt,
Rohit Sacheva,
Selma Masic,
Edith Yuan,
Trenten Fenster,
Michael Martinez,
Supna Saxena,
Theodore Nicolaides,
Shirin Ilkhanizadeh,
Mitchel S. Berger,
Evan Y. Snyder,
William A. Weiss,
Johan Jakobsson,
Anders I. Persson
Publication year - 2019
Publication title -
cell reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.264
H-Index - 154
eISSN - 2639-1856
pISSN - 2211-1247
DOI - 10.1016/j.celrep.2019.07.071
Subject(s) - cancer research , sox9 , microrna , neurogenesis , psychological repression , stem cell , downregulation and upregulation , glioma , glioblastoma , phenotype , kinase , biology , microbiology and biotechnology , neuroscience , gene expression , gene , genetics
Identifying cellular programs that drive cancers to be stem-like and treatment resistant is critical to improving outcomes in patients. Here, we demonstrate that constitutive extracellular signal-regulated kinase 1/2 (ERK1/2) activation sustains a stem-like state in glioblastoma (GBM), the most common primary malignant brain tumor. Pharmacological inhibition of ERK1/2 activation restores neurogenesis during murine astrocytoma formation, inducing neuronal differentiation in tumorspheres. Constitutive ERK1/2 activation globally regulates miRNA expression in murine and human GBMs, while neuronal differentiation of GBM tumorspheres following the inhibition of ERK1/2 activation requires the functional expression of miR-124 and the depletion of its target gene SOX9. Overexpression of miR124 depletes SOX9 in vivo and promotes a stem-like-to-neuronal transition, with reduced tumorigenicity and increased radiation sensitivity. Providing a rationale for reports demonstrating miR-124-induced abrogation of GBM aggressiveness, we conclude that reversal of an ERK1/2-miR-124-SOX9 axis induces a neuronal phenotype and that enforcing neuronal differentiation represents a therapeutic strategy to improve outcomes in GBM.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom